Lyell Immunopharma, Inc.: insider trading
92 trades by 21 directors, officers and 10% owners since 2021, from their SEC Form 4 and 5 filings.
Bought, 12 months
$37.5 M
4 purchases by 4 insiders
Sold, 12 months
$613 K
29 sales by 7 insiders
Bought, 3 months
$25.0 M
2 purchases
Sold, 3 months
$216 K
9 sales
Insider buying and selling by month
Open-market purchases and sales by value, last three years.
Insiders (21)
Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.
| Insider | Shares owned directly | Bought, 12 m | Sold, 12 m | Latest trade |
|---|---|---|---|---|
| Gary K. LeeChief Scientific Officer | 16,091 | — | $72 K | |
| Lynn SeelyPresident and CEO, Director | 63,354 | — | $355 K | |
| Stephen J. HillChief Operating Officer | 16,728 | — | $51 K | |
| Veronica Sanchez BulisVP, Corporate Controller | 14,383 | — | $100 K | |
| ARCH Venture Fund XIII, L.P.10% owner | — | $25.0 M | — | |
| ARCH Venture Partners IX, LLC10% owner | — | — | — | |
| Jarrad Mattieu AguirreChief Medical Officer | 19,857 | — | $4 K | |
| David ShookChief Medical Officer | 20,423 | — | $31 K | |
| Innovative Cellular Therapeutics Holdings Ltd10% owner | 2.82 M | — | $274 | |
| ARCH Venture Partners IX Overage, L.P.10% owner | — | — | — | |
| Paul L. Berns10% owner | — | $12.5 M | — | |
| Charles W. NewtonChief Financial Officer | 15,306 | — | — | |
| Otis W. BrawleyDirector | 35,640 | — | — | |
| Sumant RamachandraDirector | — | — | — | |
| Richard KlausnerDirector | — | — | — | |
| Matthew LangChief Business Officer | 162,500 | — | — | |
| Hans Edgar BishopDirector | 4.69 M | — | — | |
| Cathy FriedmanDirector | — | — | — | |
| ARCH Venture Fund IX, L.P.10% owner | — | — | — | |
| Glaxosmithkline PLC10% owner | — | — | — | |
| Robert NelsenDirector, 10% owner | — | — | — |
Trades#
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Lynn SeelyPresident and CEO, Director | Sell | -545 | $15.93 | $9 K | 63,354 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Sell | -88 | $15.93 | $1 K | 16,728 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Sell | -129 | $15.93 | $2 K | 16,091 | Form 4 |
| filed | Veronica Sanchez BulisVP, Corporate Controller | Sell | -416 | $15.93 | $7 K | 14,383 | Form 4 |
| filed | ARCH Venture Fund XIII, L.P.10% owner | Buyindirect | +2.32 M | $10.77 | $25.0 M | 3.75 M | Form 4 |
| filed | ARCH Venture Partners IX, LLC10% owner | Buyindirect | +2.32 M | $10.77 | — | 3.75 M | Form 4 |
| filed | Jarrad Mattieu AguirreChief Medical Officer | Sell | -422 | $8.630 | $4 K | 19,857 | Form 4 |
| filed | David ShookChief Medical Officer | Sell | -500 | $12.70 | $6 K | 20,423 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Sell | -9,589 | $15.54 | $149 K | 63,899 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Sell | -989 | $15.54 | $15 K | 16,816 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Sell | -1,457 | $15.54 | $23 K | 16,220 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Sell | -89 | $14.34 | $1 K | 17,805 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Sell | -390 | $14.34 | $6 K | 73,488 | Form 4 |
| filed | Veronica Sanchez BulisVP, Corporate Controller | Sell | -621 | $14.34 | $9 K | 14,799 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Sell | -131 | $14.34 | $2 K | 17,677 | Form 4 |
| filed | Innovative Cellular Therapeutics Holdings Ltd10% owner | Other | -38,500 | — | — | 2.82 M | Form 4 |
| filed | Innovative Cellular Therapeutics Holdings Ltd10% owner | Other | -44,000 | — | — | 2.77 M | Form 4 |
| filed | Innovative Cellular Therapeutics Holdings Ltd10% owner | Sell10b5-1 plan | -10 | $13.70 | $137 | 2.86 M | Form 4 |
| filed | Innovative Cellular Therapeutics Holdings Ltd10% owner | Sell10b5-1 plan | -10 | $13.73 | $137 | 2.86 M | Form 4 |
| filed | Innovative Cellular Therapeutics Holdings Ltd10% owner | Other | -76,000 | — | — | 2.86 M | Form 4 |
| filed | Innovative Cellular Therapeutics Holdings Ltd10% owner | Other | -66,500 | — | — | 2.93 M | Form 4 |
| filed | David ShookChief Medical Officer | Sell | -1,977 | $12.64 | $25 K | 20,923 | Form 4 |
| filed | Veronica Sanchez BulisVP, Corporate Controller | Sell | -217 | $18.91 | $4 K | 15,420 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Sell | -89 | $18.92 | $2 K | 17,894 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Sell | -130 | $18.92 | $2 K | 17,808 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Sell | -388 | $18.91 | $7 K | 73,878 | Form 4 |
| filed | ARCH Venture Partners IX Overage, L.P.10% owner | Buyindirect | +488,090 | $25.61 | — | 1.43 M | Form 4 |
| filed | Paul L. Berns10% owner | Buyindirect | +488,090 | $25.61 | $12.5 M | 1.43 M | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Sell | -7,455 | $23.39 | $174 K | 74,266 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Sell | -1,671 | $23.39 | $39 K | 16,938 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Sell | -1,236 | $23.39 | $29 K | 17,795 | Form 4 |
| filed | Veronica Sanchez BulisVP, Corporate Controller | Grant or award | +8,750 | — | — | 15,891 | Form 4 |
| filed | Veronica Sanchez BulisVP, Corporate Controller | Sell | -254 | $23.12 | $6 K | 15,637 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Sell | -109 | $23.12 | $3 K | 19,031 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Sell | -438 | $23.12 | $10 K | 81,721 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Sell | -147 | $23.12 | $3 K | 18,609 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Grant or award | +4,000 | — | — | 19,140 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Grant or award | +20,000 | — | — | 82,159 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Grant or award | +4,000 | — | — | 18,756 | Form 4 |
| filed | Veronica Sanchez BulisVP, Corporate Controller | Sell | -936 | $32.32 | $30 K | 7,141 | Form 4 |
| filed | Veronica Sanchez BulisVP, Corporate Controller | Sell | -1,136 | $38.67 | $44 K | 8,077 | Form 4 |
| filed | Veronica Sanchez BulisVP, Corporate Controller | Sell | -239 | $16.10 | $4 K | 9,213 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Sell | -412 | $16.11 | $7 K | 67,159 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Sell | -138 | $16.16 | $2 K | 15,366 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Sell | -95 | $16.12 | $2 K | 15,750 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Sell | -1,004 | $10.54 | $11 K | 15,845 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Sell | -1,453 | $10.54 | $15 K | 15,504 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Sell | -7,257 | $10.54 | $76 K | 67,571 | Form 4 |
| filed | Charles W. NewtonChief Financial Officer | Sell | -1,453 | $10.54 | — | 15,306 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Grant or award | +8,000 | — | — | 16,849 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Grant or award | +8,000 | — | — | 16,957 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Grant or award | +40,000 | — | — | 74,828 | Form 4 |
| filed | Charles W. NewtonChief Financial Officer | Grant or award | +8,000 | — | — | 16,759 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Sell | -406 | $10.34 | $4 K | 34,828 | Form 4 |
| filed | Charles W. NewtonChief Financial Officer | Sell | -136 | $10.34 | $1 K | 8,759 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Sell | -94 | $10.34 | $972 | 8,849 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Sell | -136 | $10.34 | — | 8,957 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Sell | -131 | $10.53 | — | 9,093 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Sell | -391 | $10.53 | $4 K | 35,234 | Form 4 |
| filed | Charles W. NewtonChief Financial Officer | Sell | -131 | $10.53 | $1 K | 8,895 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Sell | -91 | $10.53 | $958 | 8,943 | Form 4 |
| filed | David ShookChief Medical Officer | Grant or award | +21,900 | — | — | 21,900 | Form 4 |
| filed | Otis W. BrawleyDirector | Buy | +35,640 | $0.560 | $20 K | 35,640 | Form 4 |
| filed | Sumant RamachandraDirector | Buyindirect | +200,000 | $0.580 | $116 K | 200,000 | Form 4 |
| filed | Charles W. NewtonChief Financial Officer | Buyindirect | +200,000 | $0.560 | $112 K | 200,000 | Form 4 |
| filed | Richard KlausnerDirector | Buyindirect | +158,000 | $0.600 | $95 K | 843,365 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Buy | +175,000 | $0.610 | $107 K | 712,500 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Grant or award | +112,500 | — | — | 176,696 | Form 4 |
| filed | Charles W. NewtonChief Financial Officer | Grant or award | +112,500 | — | — | 172,725 | Form 4 |
| filed | Matthew LangChief Business Officer | Grant or award | +112,500 | — | — | 162,500 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Grant or award | +337,500 | — | — | 537,500 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Grant or award | +112,500 | — | — | 172,899 | Form 4 |
| filed | Matthew LangChief Business Officer | Grant or award | +50,000 | — | — | 50,000 | Form 4 |
| filed | Stephen J. HillChief Operating Officer | Grant or award | +40,000 | — | — | 48,928 | Form 4 |
| filed | Gary K. LeeChief Scientific Officer | Grant or award | +40,000 | — | — | 52,700 | Form 4 |
| filed | Charles W. NewtonChief Financial Officer | Grant or award | +40,000 | — | — | 48,729 | Form 4 |
| filed | Lynn SeelyPresident and CEO, Director | Grant or award | +200,000 | — | — | 200,000 | Form 4 |
| filed | Richard KlausnerDirector | Sellindirect | -58,020 | $2.280 | $132 K | 930,880 | Form 4 |
| filed | Richard KlausnerDirector | Sellindirect | -11,100 | $6.400 | $71 K | 988,900 | Form 4 |
| filed | Hans Edgar BishopDirector | Option exercise | +145,380 | $0.100 | $15 K | 4.69 M | Form 4 |
| filed | Hans Edgar BishopDirector | Option exercise | +993,428 | $0.100 | $99 K | 4.54 M | Form 4 |
| filed | Cathy FriedmanDirector | Otherindirect | -3.77 M | — | — | 0 | Form 4 |
| filed | Cathy FriedmanDirector | Otherindirect | +218,722 | — | — | 236,370 | Form 4 |
| filed | Hans Edgar BishopDirector | Conversion | +546,806 | — | — | 3.55 M | Form 4 |
| filed | ARCH Venture Fund IX, L.P.10% owner | Conversionindirect | +18.21 M | — | — | 18.21 M | Form 4 |
| filed | Glaxosmithkline PLC10% owner | Conversionindirect | +30.25 M | — | — | 30.25 M | Form 4 |
| filed | Cathy FriedmanDirector | Conversionindirect | +3.77 M | — | — | 3.77 M | Form 4 |
| filed | Richard KlausnerExecutive Chairman, Director | Conversionindirect | +3.77 M | — | — | 3.77 M | Form 4 |
| filed | Robert NelsenDirector, 10% owner | Conversionindirect | +18.21 M | — | — | 18.21 M | Form 4 |
| filed | ARCH Venture Fund IX, L.P.10% owner | Conversionindirect | +18.21 M | — | — | 18.21 M | Form 4 |
| filed | Cathy FriedmanDirector | Buyindirect | +17,648 | $17.00 | $300 K | 17,648 | Form 4 |
| filed | Robert NelsenDirector, 10% owner | Conversionindirect | +18.21 M | — | — | 18.21 M | Form 4 |
Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice